Phase 1:
To understand the needs and interest of the targeted population, this mixed method project will first examine e-cigarette use and interest in quitting among a cohort of AYA survivors who range in age from 13-24 on the day of consent and are at least 3 months post treatment completion. The study team will also explore demographic, medical, and psychosocial factors associated with vaping behaviors (Objective 1). Research participants will complete study assessments via REDCap, a HIPAA-compliant, password-protected, data collection and storage platform. AYA survivors who endorse current vaping and desire to quit (N=25) and healthcare providers engaged in AYA oncology care (N=15), will be asked to complete questionnaires related to attitudes, beliefs, and knowledge about e-cigarette use. The participants will also be asked to provide feedback on preferences for systematically integrating e-cigarette use screening and referral processes within AYA oncology clinic systems. The study team will also seek provider feedback on current processes (e.g., workflow), needs, and barriers for assessing ecigarette use and providing vaping cessation referrals (Objective 2).
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
